Yaohai Bio-Pharma established its mRNA CRO platform in 2022 and has supported over 800 RNA projects to date, partnering with universities, research institutes, and many biotech companies. Leveraging GMP plasmid production, robust IVT systems, advanced purification, and LNP delivery technologies, we now provide integrated mRNA solutions from early R&D to commercial manufacturing, accelerating project timelines for global clients.
Building on 10+ years of experience in mRNA field and fully integrated mRNA CRDMO capabilities, Yaohai Bio-Pharma proudly present the “RNASUP” CRDMO platform—covering plasmid preparation, mRNA synthesis & purification, LNP encapsulation, GMP production, and regulatory support—delivering seamless services for
Our end-to-end mRNA CRDMO platform supports the project from R&D (mg) to commercial (tens of grams) scale, fully meeting EMA and FDA GMP requirements.
.Yaohai Bio-Pharma has established robust and mature platforms for plasmid production, mRNA synthesis, and LNP formulation. The company provides end-to-end solutions to global clients across key development stages, including early R&D, clinical-stage process development, GMP manufacturing, analytical testing, drug product fill-finish, and regulatory submission support.
Yaohai Bio-Pharma delivers tailored solutions for global clients, meeting diverse project requirements with excellence and efficiency.
Proven track record of over 100 successful projects, spanning preclinical studies and Phase I/II/III clinical trials, including US–China dual submissions and Australian regulatory filings.
A robust GMP-aligned quality system with standardized SOPs, fully compliant with global regulatory guidelines across the entire product lifecycle.
Powered by industry-leading scientists and cross-functional experts, our team delivers CRDMO projects with speed, precision, and deep technical insight.
